A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer
Clinical trial NCT05183958 · UNKNOWN
Trial details
- NCT number
- NCT05183958
- Sponsor
- Zhejiang Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-31
- Primary completion
- 2023-12-01
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.